864953-29-7

Basic information

• Product Name: BMS 663068
• Synonyms: BMS 663068;BMS663068;BMS-663068;BMS-663068-03;Fostemsavir(BMS-663068);Fostemsavir;1-(4-Benzoyl-1-piperazinyl)-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-ethanedione;[3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
• CAS NO: 864953-29-7
• Molecular Formula: C₂₅H₂₆N₇O₈P
• Molecular Weight: 583.489801
• Mol File: 864953-29-7.mol

Chemical Properties

• Boiling Point: 904.1±75.0 °C(Predicted)
• Appearance: /
• Density: 1.60±0.1 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 1.39±0.10(Predicted)
• CAS DataBase Reference: BMS 663068(CAS DataBase Reference)
• NIST Chemistry Reference: BMS 663068(864953-29-7)
• EPA Substance Registry System: BMS 663068(864953-29-7)

Safety Data

• Hazardous Substances Data: 864953-29-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BMS 663068 is used as an antiviral agent for the treatment of HIV/AIDS. It works by inhibiting the HIV-1 envelope glycoprotein gp120, preventing the virus from entering human cells and thus reducing viral replication and spread.
Used in HIV/AIDS Research:
BMS 663068 is used as a research tool in the study of HIV/AIDS, particularly in understanding the mechanisms of viral entry and the development of resistance to current antiretroviral drugs. Its strong antiviral activity against a broad range of HIV-1 strains makes it a valuable asset in the search for new and more effective treatments.
Used in Clinical Trials:
BMS 663068 is being evaluated in clinical trials as a potential component of combination therapy for HIV infection. Its unique mechanism of action and efficacy against drug-resistant strains of HIV-1 make it a promising candidate for improving treatment outcomes and addressing the unmet needs of individuals with HIV/AIDS.
Used in Drug Development:
BMS 663068 represents a new class of HIV entry inhibitors, which has implications for the development of new antiviral drugs and therapeutic strategies. Its discovery and ongoing evaluation in clinical trials contribute to the advancement of HIV/AIDS treatment options and the ongoing fight against the virus.

Downstream Products

• 864953-39-9 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine di-tris salt 
• 864953-39-9 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl hydrogen phosphate 

Relevant articles and documents

Prodrugs of piperazine and substituted piperidine antiviral agents

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.